STO : ABLI.ST

Abliva AB (publ)

$0.444 SEK

$0.0 (0.23%)

Volume
565.71K
Average Volume
3.87M
Market Capitalization
$715.67M
P/E Ratio
-4.91
Dividend Yield
0.00%
Price Target
Year High
$0.46
Year Low
$0.11
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$4.13
Company Overview

STO

Ellen K. Donnelly

Biotechnology

Healthcare

ABLI.ST

6

SE

SEK

https://abliva.com

46 4 62 75 62 20

N/A

N/A

Liquidity Metrics

0.00

4.13

4.13

2.75

0.00

Sales & Valuation

$137K

5223.90

7.60

-6.88

-0.10

Profitability

-$0.0904

-$95.51M

-69714.60%

-69721.17%

-144.27%

-129.85%

P/E Metrics

-4.91

-0.20

-0.20

Analyst Price Target & Rating

N/A

0/5

0 Analysts

%

Financial Health Scores

14.16

2/9

$37.08M

$73.55M

$11.86M

-$89.9M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Ellen K. Donnelly Chief Executive Officer
Eskil Elmér Chief Scientific Officer & Vice President of Discovery
Eleonor Åsander Frostner Communications Officer & Lab Manager
Lars Vedin Consultant
Magnus Hansson Chief Medical Officer and Vice President of Preclinical & Clinical Development
Dag Nesse Vice President of Clinical Operations
Catharina Jz Johansson Deputy Chief Executive Officer, Chief Financial Officer & Vice President of Investor Relations
Poll Results

No votes yet today — be the first to share your view!

About Abliva AB (publ) (STO:ABLI.ST) Stock

Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously ... been known as NeuroVive Pharmaceutical AB (publ).

Frequently Asked Questions

What is the current Abliva AB (publ) (ABLI.ST) stock price?

Abliva AB (publ)(STO:ABLI.ST) stock price is $0.444 in the last trading session. During the trading session, ABLI.ST stock reached the peak price of $0.455 while $0.1136 was the lowest point it dropped to. The percentage change in ABLI.ST stock occurred in the recent session was 0.23% while the dollar amount for the price change in ABLI.ST stock was $0.0.

ABLI.ST's industry and sector of operation?

The STO listed ABLI.ST is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ABLI.ST?

Ellen K. Donnelly | Chief Executive Officer
Eskil Elmér | Chief Scientific Officer & Vice President of Discovery
Eleonor Åsander Frostner | Communications Officer & Lab Manager
Lars Vedin | Consultant
Magnus Hansson | Chief Medical Officer and Vice President of Preclinical & Clinical Development

How many employees does ABLI.ST have?

Number of ABLI.ST employees currently stands at 6. ABLI.ST operates from Medicon Village, Lund, None 223 81, SE.

Link for ABLI.ST official website?

Official Website of ABLI.ST is: https://abliva.com

How do I contact ABLI.ST?

ABLI.ST could be contacted at phone #46 4 62 75 62 20 and can also be accessed through its website. ABLI.ST operates from Medicon Village, Lund, None 223 81, SE.

How many shares of ABLI.ST are traded daily?

The average number of ABLI.ST shares traded daily for last 3 months was 3.87M.

What is the market cap of ABLI.ST currently?

The market value of ABLI.ST currently stands at $715.67M with its latest stock price at $0.444